by EpicentRx | Jul 12, 2022 | 2022, Press Releases
BRISBANE, AUSTRALIA, July 12, 2022 – University of Queensland researchers will partner with American biopharmaceutical company EpicentRx Inc. to evaluate new treatments for Parkinson’s disease (PD), speeding up development of potential new therapies. UQ and EpicentRx...
by EpicentRx | Jul 12, 2022 | 2022, Press Releases
The $500,000 USD grant will support study of EpicentRx’s lead small molecule inflammasome inhibitor TORREY PINES, Calif., July 12, 2022 — EpicentRx Inc. (“EpicentRx”), a late-stage biopharmaceutical company developing platforms that treat and target multiple...
by EpicentRx | Jun 20, 2022 | Blog
In June, EpicentRx was truly “on the go,” arriving at ASCO in Chicago directly from Scottsdale, Arizona where the company just one day prior presented data on the lipid-lowering effects of its small molecule, RRx-001, at the National Lipid Association (NLA), hence...
by EpicentRx | Jun 13, 2022 | Blog
On June 3, 2022, at 11 a.m., EpicentRx’s Chief Development Officer Bryan Oronsky and Senior Director of Operations and Corporate Development Scott Caroen traveled from Northern California. There, temperatures are moderate, even in the summer. But then they touched...
